相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease
Masato Muraki et al.
BMC PULMONARY MEDICINE (2021)
Comparisons of exacerbations and mortality among LAMA/LABA combinations in stable chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis
Hyun Woo Lee et al.
RESPIRATORY RESEARCH (2020)
Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD
Timothy E. Albertson et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2019)
Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol
Chad Moretz et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2019)
Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide
Erminia Ridolo et al.
PATIENT PREFERENCE AND ADHERENCE (2019)
The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects
Eric Derom et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2019)
Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study
Masakazu Ichinose et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2018)
Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial
Peter M. A. Calverley et al.
LANCET RESPIRATORY MEDICINE (2018)
Optimal Bronchodilation for COPD Patients: Are All Long-Acting beta(2)-Agonist/Long-Acting Muscarinic Antagonists the Same?
Marc Miravitlles et al.
TUBERCULOSIS AND RESPIRATORY DISEASES (2018)
Dual bronchodilation in COPD: lung function and patient-reported outcomes - a review
David Price et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2017)
Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies
Edward Kerwin et al.
LUNG (2017)
In vitro dose comparison of Respimat® inhaler with dry powder inhalers for COPD maintenance therapy
Anna-Maria Ciciliani et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2017)
Comprehensive assessment of the safety of olodaterol 5 μg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2-agonist formoterol
Andrea Koch et al.
NPJ PRIMARY CARE RESPIRATORY MEDICINE (2017)
Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study
Gregory J. Feldman et al.
ADVANCES IN THERAPY (2017)
How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?
Kai M. Beeh et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2017)
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report
Claus F. Vogelmeier et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2017)
Long-Acting Muscarinic Antagonists for Difficult-to-Treat Asthma: Emerging Evidence and Future Directions
Adeeb Bulkhi et al.
DRUGS (2016)
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD
Jadwiga A. Wedzicha et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Treatment patterns in COPD patients newly diagnosed in primary care. A population-based study
Miriam Barrecheguren et al.
RESPIRATORY MEDICINE (2016)
The efficacy and safety of combined tiotropium and olodaterol via the Respimat® inhaler in patients with COPD: results from the Japanese sub-population of the Tonado® studies
Masakazu Ichinose et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2016)
A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 mu g on health-related quality of life in patients with COPD
Thomas M. Siler et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2016)
Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting 2-agonists: a systematic review and network meta-analysis
Max Schlueter et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2016)
UK-specific cost-effectiveness of tiotropium
Abigail Tebboth et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2016)
Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4)
Roland Buhl et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease
Kai-Michael Beeh et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2015)
A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive pulmonary disease
Guy F. Joos et al.
RESPIRATORY MEDICINE (2015)
Tiotropium plus olodaterol shows clinically meaningful improvements in quality of life
Dave Singh et al.
RESPIRATORY MEDICINE (2015)
Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies
Andrea Koch et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2014)
Efficacy and safety of olodaterol once daily delivered via Respimat (R) in patients with GOLD 2-4 COPD: results from two replicate 48-week studies
Gary T. Ferguson et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2014)
Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials
Marc Decramer et al.
LANCET RESPIRATORY MEDICINE (2014)
The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2-4 COPD: results from two 6-week crossover studies
Gregory J. Feldman et al.
SPRINGERPLUS (2014)
Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study
Marc L. Decramer et al.
LANCET RESPIRATORY MEDICINE (2013)
Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study
Jadwiga A. Wedzicha et al.
LANCET RESPIRATORY MEDICINE (2013)
β2 long-acting and anticholinergic drugs control TGF-β1-mediated neutrophilic inflammation in COPD
Mirella Profita et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2012)
Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD
Claus Vogelmeier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide
Jadwiga A. Wedzicha et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
分享论文
